Recruiting Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis NCT06747858 Conditions CFTR Gene Mutation, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, +6 more Locations University of Arizona — Tucson, Arizona, United States University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States Children's Hospital of Los Angeles — Los Angeles, California, United States Children's National Hospital — Washington D.C., District of Columbia, United States View all 13 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy NCT05818319 Conditions CFTR Gene Mutation, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, +7 more Locations Department of Infectious Diseases, Aarhus University Hospital — Aarhus C, Central Jutland, Denmark View Trial Details
Completed Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy NCT07632768 Conditions CFTR Gene Mutation, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, +11 more Locations Riley Hospital for Children — Indianapolis, Indiana, United States View Trial Details
